Evolving Pharmacotherapies for the Treatment of Metastatic Melanoma | Zendy

April K.S. Salama | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evolving Pharmacotherapies for the Treatment of Metastatic Melanoma

Author(s) -

April K.S. Salama

Publication year - 2013

Publication title -

clinical medicine insights oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.601

H-Index - 26

ISSN - 1179-5549

DOI - 10.4137/cmo.s9565

Subject(s) - medicine , melanoma , immunotherapy , metastatic melanoma , disease , targeted therapy , ctla 4 , immunology , oncology , intensive care medicine , immune system , cancer , cancer research , t cell

Metastatic melanoma remains a difficult disease to treat, and long term survivors are rare. Over the past few years, however, breakthroughs in both immunotherapy as well as targeted agents have had a tremendous impact on patients diagnosed with this disease. This review summarizes recent advances in systemic therapies for melanoma, including immune modulators directed against cytotoxic T lymphocyte associated antigen-4 (CTLA-4) and programmed death-1 (PD-1), as well as a number of targeted agents. These approaches hold great promise as the landscape of therapeutic options for advanced melanoma continues to evolve.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research